ChromoGenics announce updated degree of assurance
The Board of Directors of ChromoGenics AB (“the Company”) announces today that the new issue of shares with preferential rights for the Company's existing shareholders which was announced on February 8, 2022 (the “Rights Issue”) has been secured to approximately 79.9 percent, in accordance with the communicated intention. Senior executives and board members of the Company have entered into subscription commitments and guarantee commitments for a total of approximately SEK 0.8 million, with the result that the Rights Issue is now secured at approximately SEK 54.4 million.